Methylprednisolone
Other / unclassified targets AQP2
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MEDROL | — | 1957-10-24 | fda.gov ↗ |
Trials 390 · started per year
Also used as a comparator or background therapy in 646 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 012 trials | ||||||
| Phase 0 | NCT07519005 Background | Jan → Feb 2026 overdue | liver failure | Xijing Hospital | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06081101 Comparator | Jan 2025 → Jun 2026 overdue | arthritis, sacroiliac | McMaster University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06707389 Comparator | Dec 2024 → Jun 2026 overdue | sensorineural hearing loss disorder, sudden hearing loss disorder | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06119490 Background | Jul 2023 → Jul 2026 overdue | toxic epidermal necrolysis | Peng Zhang | Recruiting | No outcome recorded |
| Phase 0 | NCT05742061 Comparator | Apr → Oct 2023 | osteoarthritis, knee | Benha University | Unknown | No outcome recorded |
| Phase 0 | NCT06802432 Comparator | Jan → Jul 2022 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT02995083 Comparator | Jun 2017 → Jan 2018 | osteoarthritis, knee | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT03059979 Comparator | Jan 2017 → Jul 2021 | Raynaud disease, systemic sclerosis | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 0 | NCT02680548 Comparator | Nov 2015 → Dec 2017 | neuropathy, painful | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 0 | NCT02212210 Comparator | Feb 2012 → Apr 2014 | pregnancy disorder | Medical University of South Carolina | Terminated | No outcome recorded |
| Phase 0 | NCT02252809 Comparator | Nov 2008 → Apr 2009 | — | Brugmann University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT00370799 Comparator | Jan 2007 → Dec 2009 | — | Pain Management Center of Paducah | Completed | No outcome recorded |
| Phase 138 trials | ||||||
| Phase 1 | NCT06917859 Comparator | Feb 2025 → Feb 2026 overdue | acute kidney injury | Ain Shams University | Recruiting | No outcome recorded |
| Phase 1 | NCT06225310 Background | Aug 2024 → Apr 2027 expected | plasma cell myeloma | Oncotherapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05823675 Background | May 2023 → Oct 2024 | acute graft versus host disease | Biotech Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05302388 Background | Apr 2022 → Jan 2023 | — | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 1 | NCT04599634 Background | Dec 2021 → Mar 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT04666129 Background | Feb 2021 → May 2024 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04519476 Background | Nov 2020 → Dec 2023 | refractory plasma cell neoplasm | Oncotherapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT04532775 Background | Aug → Dec 2020 | peripheral neuropathy | Fayoum University | Unknown | No outcome recorded |
| Phase 1 | NCT04051203 Comparator | Feb 2019 → Dec 2023 | headache disorder, neuralgia | University of Calgary | Completed | No outcome recorded |
| Phase 1 | NCT05053477 Comparator | Sep 2018 → Nov 2022 | carpal tunnel syndrome | Alexandria University | Unknown | No outcome recorded |
| Phase 1 | NCT03605238 Background | Aug 2018 → Aug 2019 | neuromyelitis optica spectrum disorder with anti-AQP4 antibodies | Chinese PLA General Hospital | Withdrawn | No outcome recorded |
| Phase 1 | NCT03497273 Background | Mar 2018 → Nov 2019 | acute graft versus host disease | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02872597 Background | Sep 2016 → Aug 2018 | status asthmaticus | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02867800 Background | Jul 2016 → Dec 2021 | graft versus host disease, sickle cell disease | Monica Bhatia | Completed | No outcome recorded |
| Phase 1 | NCT02779283 Background | Jan 2016 → Apr 2018 | acute lymphoblastic leukemia, acute myeloid leukemia | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02293109 Background | Dec 2015 → Dec 2017 | adult acute lymphoblastic leukemia | Mehrdad Abedi, MD | Completed | No outcome recorded |
| Phase 1 | NCT02583594 Background | Dec 2015 → Mar 2016 | multiple sclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT02614612 Background | Dec 2015 → Jun 2016 | acute graft versus host disease | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02087813 Background | Mar 2014 → Mar 2016 | neuromyelitis optica | Stanford University | Withdrawn | No outcome recorded |
| Phase 1 | NCT01977781 Comparator | Dec 2013 → Sep 2014 | chronic graft versus host disease | Massachusetts Eye and Ear Infirmary | Completed | No outcome recorded |
| Phase 1 | NCT01331018 Background | Feb 2012 → Feb 2024 | Fanconi anemia | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01390441 Background | Jul 2011 → Apr 2014 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01267201 Comparator | Nov → Dec 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01186328 Background | Aug 2010 → Jan 2012 | T-cell acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Terminated | No outcome recorded |
| Phase 1 | NCT01049451 Comparator | Nov 2009 → Jun 2013 | multiple sclerosis | University of Southern California | Completed | No outcome recorded |
| Phase 1 | NCT00849888 Background | Apr 2008 → Feb 2011 | DiGeorge syndrome | Sumitomo Pharma Switzerland GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT00279903 Comparator | Nov 2005 → Aug 2008 | osteoarthritis, knee | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00278564 Background | Sep 2005 → Jul 2016 | myopathy | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT00376480 Background | Jun 2005 → Jun 2010 | leukemia, myelodysplastic syndrome | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00112645 Background | Apr 2005 → Apr 2010 | childhood malignant neoplasm, neuroblastoma, sarcoma | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00436761 Background | May 2004 → ? | childhood malignant neoplasm | Milton S. Hershey Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT00054236 Background | May 2002 → Mar 2011 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloproliferative neoplasm +1 | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00053105 Background | Feb 2002 → ? | lymphoma | Theradex | Unknown | No outcome recorded |
| Phase 1 | NCT00424489 Background | Feb 2002 → Jun 2016 | myasthenia gravis | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT00017628 Background | Apr 2001 → ? | multiple sclerosis | Northwestern Memorial Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00005988 Background | Feb 2000 → Jun 2001 | graft versus host disease, leukemia, myelodysplastic syndrome, plasma cell myeloma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00004232 Background | Oct 1999 → Oct 2002 | graft versus host disease, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +2 | Northwestern University | Completed | No outcome recorded |
| Phase 1 | NCT00004904 Background | Oct 1999 → Jul 2000 | graft versus host disease, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +3 | Northwestern University | Completed | No outcome recorded |
| Phase 1/246 trials | ||||||
| Phase 1/2 | NCT07287397 Background | Dec 2025 → Oct 2027 expected | amyotrophic lateral sclerosis | Vector Y Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07052929 Background | Dec 2025 → Oct 2027 expected | X-linked myotubular myopathy | Astellas Gene Therapies | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07285889 Background | Dec 2025 → Dec 2027 expected | acute graft versus host disease | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07270549 Background | Nov 2025 → Dec 2032 expected | CTNNB1-related neurodevelopmental disorder and/or vitreoretinopathy | CTNNB1 Foundation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07101367 Comparator | Sep 2025 → Aug 2026 overdue | autoinflammatory syndrome, coronary artery disorder | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06656962 Background | Oct 2024 → Dec 2025 overdue | pauci-immune glomerulonephritis with ANCA | Renmin Hospital of Wuhan University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05789589 Background | Nov 2023 → Mar 2027 | metastatic malignant neoplasm in the brain | Baptist Health South Florida | Suspended | No outcome recorded |
| Phase 1/2 | NCT04988425 Comparator | Sep 2022 → Aug 2023 | spinal cord injury | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04411654 Background | Jun 2021 → May 2028 expected | Gaucher disease type II | Prevail Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04408625 Background | Nov 2020 → Nov 2029 expected | frontotemporal dementia | Prevail Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04591600 Background | Jul → Sep 2020 | COVID-19 | Alkarkh Health Directorate-Baghdad | Completed | No outcome recorded |
| Phase 1/2 | NCT04294459 Background | Jun 2020 → May 2022 | immune system disorder | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT04220632 Background | Jun → Oct 2020 | acute graft versus host disease | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT06790615 Comparator | Jun → Dec 2020 | ganglion or cyst of synovium/tendon/bursa | Benazir Bhutto Hospital, Rawalpindi | Completed | No outcome recorded |
| Phase 1/2 | NCT04127578 Background | Jan 2020 → Mar 2031 expected | Parkinson disease | Prevail Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03721965 Background | Dec 2019 → Feb 2020 | acute graft versus host disease | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT04066114 Background | Dec 2019 → Sep 2023 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT04224558 Background | Nov 2019 → Sep 2027 expected | Crohn disease | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03952637 Background | Aug 2019 → Jan 2028 expected | GM1 gangliosidosis | National Human Genome Research Institute (NHGRI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03752307 Background | Feb 2019 → Jul 2023 | multiple sclerosis | University of New Mexico | Completed | No outcome recorded |
| Phase 1/2 | NCT04397367 Background | Jan 2019 → Jul 2020 | acute graft versus host disease | Chinese PLA General Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03745586 Background | Dec 2018 → Nov 2020 | temporal arteritis | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 1/2 | NCT02464657 Background | Jul 2015 → May 2020 | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02472054 Background | Jun 2015 → Sep 2019 | hemophagocytic syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1/2 | NCT02348216 Background | Apr 2015 → Jul 2023 | follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Kite, A Gilead Company | Completed | No outcome recorded |
| Phase 1/2 | NCT01783847 Comparator | Feb 2015 → Apr 2016 | optic nerve disorder | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT02431403 Background | Feb 2015 → Feb 2020 | non-Hodgkin lymphoma | Pusan National University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02243436 Background | Nov 2014 → Jan 2019 | classic Hodgkin lymphoma | Spanish Lymphoma Cooperative Group | Completed | No outcome recorded |
| Phase 1/2 | NCT02282514 Background | Oct 2014 → Aug 2019 | classic stiff person syndrome | Northwestern University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01875237 Background | Dec 2013 → Mar 2017 | leukemia, myeloproliferative neoplasm, plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01647685 Comparator | May 2012 → May 2013 | atherosclerosis | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 1/2 | NCT01354483 Background | Sep 2011 → Sep 2013 | spinal cord injury | China Spinal Cord Injury Network | Completed | No outcome recorded |
| Phase 1/2 | NCT02340936 Background | Jan 2011 → Sep 2016 | diffuse large B-cell lymphoma | Spanish Lymphoma Cooperative Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01154387 Background | Jul 2010 → Jun 2013 | end stage renal failure | Tolera Therapeutics, Inc | Unknown | No outcome recorded |
| Phase 1/2 | NCT01046786 Comparator | Jan 2010 → Oct 2013 | spinal cord injury | China Spinal Cord Injury Network | Completed | No outcome recorded |
| Phase 1/2 | NCT00787722 Background | Oct 2009 → Nov 2018 | neuromyelitis optica | Northwestern University | Completed | No outcome recorded |
| Phase 1/2 | NCT00987831 Background | May 2009 → Dec 2012 | systemic lupus erythematosus | Oklahoma Medical Research Foundation | Completed | No outcome recorded |
| Phase 1/2 | NCT00582816 Background | Aug 2008 → Aug 2015 | cancer, leukemia | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 1/2 | NCT00752479 Background | May 2008 → Jul 2013 | — | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Phase 1/2 | NCT01346085 Background | Oct 2006 → Jun 2009 | type 1 diabetes mellitus | Ospedale San Raffaele | Completed | No outcome recorded |
| Phase 1/2 | NCT00579527 Background | Dec 2005 → Dec 2011 | DiGeorge syndrome | Sumitomo Pharma Switzerland GmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT00078559 Background | Nov 2003 → Feb 2010 | kidney disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1/2 | NCT00630253 Background | Feb 2000 → Oct 2020 | Fanconi anemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1/2 | NCT00005898 Background | Feb 2000 → ? | Fanconi anemia | University of Minnesota | Completed | No outcome recorded |
| Phase 1/2 | NCT00609739 Background | Jun 1999 → Jun 2010 | leukemia | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 1/2 | NCT00002831 Background | Aug 1995 → Dec 2002 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2166 trials | ||||||
| Phase 2 | NCT07455396 Comparator | Aug 2026 → Aug 2028 expected | asthma | Johns Hopkins All Children's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07594912 Comparator | Aug 2026 → Dec 2027 expected | disease of orbital part of eye adnexa, optic nerve disorder | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07208799 Comparator | Jan → Nov 2026 expected | disorder of facial skeleton | Nishtar Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07340463 Background | Dec 2025 → Jun 2027 expected | lupus nephritis, systemic lupus erythematosus | Nanjing University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT07185633 Background | Oct 2025 → Oct 2026 expected | acute graft versus host disease | Bin Gu | Not yet recruiting | No outcome recorded |
| Show all 166 trials opens the full record — a long page | ||||||
| Phase 2/338 trials | ||||||
| Phase 2/3 | NCT07703280 Comparator | Sep 2026 → Dec 2028 expected | osteoarthritis, knee | DuoGenic StemCells Corporation (DGSC) | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07072585 Background | Aug 2026 → Sep 2035 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Children's Oncology Group | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07412470 Background | Mar 2026 → Aug 2029 expected | transplant rejection | Sanofi | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02422368 Comparator | Sep 2022 → Jun 2024 | endocrine exophthalmos | Iran University of Medical Sciences | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05951504 Comparator | Jun 2022 → Mar 2023 | suppurative periapical periodontitis | University of Manitoba | Completed | No outcome recorded |
| Phase 2/3 | NCT05748561 Comparator | Apr 2022 → Apr 2024 | toxic optic neuropathy | Asociación para Evitar la Ceguera en México | Unknown | No outcome recorded |
| Phase 2/3 | NCT04787744 Background | Jul 2021 → Sep 2026 expected | metastatic prostate carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04898231 Comparator | Dec 2020 → Dec 2023 | COVID-19–associated multisystem inflammatory syndrome in children | University of California, San Diego | Completed | No outcome recorded |
| Phase 2/3 | NCT04480775 Comparator | Jul → Dec 2020 | — | ghada fouad | Completed | No outcome recorded |
| Phase 2/3 | NCT03829566 Background | Nov 2019 → Jan 2025 | neuromyelitis optica | Northwestern University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04074187 Background | Oct 2019 → May 2021 | thrombotic thrombocytopenic purpura | Sanofi | Completed | No outcome recorded |
| Phase 2/3 | NCT03584516 Background | Jan 2019 → Nov 2023 | chronic graft versus host disease | Incyte Corporation | Terminated | No outcome recorded |
| Phase 2/3 | NCT03593902 Background | May 2018 → Oct 2019 | systemic sclerosis | Northwestern University | Terminated | No outcome recorded |
| Phase 2/3 | NCT02956122 Background | Apr 2017 → May 2018 | acute graft versus host disease | Baxalta now part of Shire | Terminated | No outcome recorded |
| Phase 2/3 | NCT03289338 Comparator | Jun 2016 → Dec 2018 | neurogenic arthropathy | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT02578394 Comparator | Apr 2016 → Jan 2022 | chronic kidney disease, gout | Mid and South Essex NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2/3 | NCT02647255 Background | Mar 2016 → Oct 2020 | IgA glomerulonephritis, acute kidney injury, rapidly progressive glomerulonephritis | Peking University First Hospital | Terminated | No outcome recorded |
| Phase 2/3 | NCT02445898 Comparator | Sep 2015 → Jan 2017 | osteoarthritis | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2/3 | NCT02542592 Comparator | Sep 2015 → Jan 2017 | osteoarthritis | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2/3 | NCT01809132 Comparator | Sep 2013 → Oct 2018 | alcoholic hepatitis | Mack Mitchell | Completed | No outcome recorded |
| Phase 2/3 | NCT01907204 Comparator | Jul → Aug 2013 | sinusitis | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| Phase 2/3 | NCT01957631 Comparator | Jun 2013 → Jun 2019 | plantar fasciitis | King Hamad University Hospital, Bahrain | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01228331 Comparator | Oct 2010 → Dec 2019 | leukemia | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Phase 2/3 | NCT01015742 Background | Nov 2009 → Dec 2012 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT00947895 Comparator | Oct 2009 → Jan 2011 | multiple sclerosis | Neurologique Foundation, Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT00891306 Background | Feb 2009 → Aug 2010 | familial lipoprotein lipase deficiency | Amsterdam Molecular Therapeutics | Completed | No outcome recorded |
| Phase 2/3 | NCT00806871 Comparator | Nov 2008 → Apr 2012 | carpal tunnel syndrome | Region Skane | Completed | No outcome recorded |
| Phase 2/3 | NCT00733096 Comparator | Aug 2008 → Mar 2011 | radiculopathy | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT00720109 Background | Jul 2008 → Dec 2014 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT00595335 Background | Apr 2008 → Mar 2013 | disease of orbital part of eye adnexa | Rebecca Bahn | Completed | No outcome recorded |
| Phase 2/3 | NCT00562835 Comparator | Feb 2008 → Feb 2009 | acute lung injury, acute respiratory distress syndrome | Catholic University of the Sacred Heart | Unknown | No outcome recorded |
| Phase 2/3 | NCT00977444 Comparator | Nov 2007 → Feb 2009 | osteoarthritis | Nucitec | Unknown | No outcome recorded |
| Phase 2/3 | NCT00455312 Background | Aug 2007 → Mar 2015 | aplastic anemia, dyskeratosis congenita | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2/3 | NCT00947765 Comparator | Jan 2007 → Jun 2008 | epicondylitis | Dojode, Chetan M., MBBS, MS | Completed | No outcome recorded |
| Phase 2/3 | NCT00104299 Background | Jan 2005 → Dec 2008 | granulomatosis with polyangiitis, microscopic polyangiitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/3 | NCT00135967 Background | May 2002 → ? | idiopathic membranous glomerulonephritis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00004255 Background | Mar 2000 → May 2003 | graft versus host disease, leukemia, myelodysplastic syndrome | Chimeric Therapies | Completed | No outcome recorded |
| Phase 2/3 | NCT01408836 Comparator | Mar 1995 → Jun 2003 | granulomatosis with polyangiitis, microscopic polyangiitis | Cambridge University Hospitals NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 3122 trials | ||||||
| Phase 3 | NCT07623668 Background | May 2026 → Dec 2027 expected | optic neuritis | Oculis | Recruiting | No outcome recorded |
| Phase 3 | NCT07478003 Comparator | Apr 2026 → Apr 2031 expected | ST-elevation myocardial infarction | Thomas Engstrom | Recruiting | No outcome recorded |
| Phase 3 | NCT07299695 Comparator | Jan 2026 → Jun 2028 expected | idiopathic pulmonary fibrosis | Argyrios Tzouvelekis | Recruiting | No outcome recorded |
| Phase 3 | NCT07420296 Background | Jan → Dec 2026 expected | neuromyelitis optica spectrum disorder with anti-AQP4 antibodies | Tianjin Medical University General Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07100990 Comparator | Jul 2025 → Apr 2029 expected | optic neuritis, transverse myelitis | Mayo Clinic | Recruiting | No outcome recorded |
| Show all 122 trials opens the full record — a long page | ||||||
| Phase 4134 trials | ||||||
| Phase 4 | NCT07546097 Comparator | Mar 2026 → Mar 2027 expected | ulcerative colitis | Yongquan Shi | Recruiting | No outcome recorded |
| Phase 4 | NCT06892210 Comparator | Mar 2026 → Aug 2030 expected | chronic obstructive pulmonary disease | Copenhagen Respiratory Research | Recruiting | No outcome recorded |
| Phase 4 | NCT06892197 Comparator | Mar 2026 → Aug 2030 expected | pneumonia | Copenhagen Respiratory Research | Recruiting | No outcome recorded |
| Phase 4 | NCT07255248 Comparator | Mar 2026 → Nov 2027 expected | — | Boston Children's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07394894 Comparator | Mar 2026 → Mar 2027 expected | plantar fasciitis | Assiut University | Not yet recruiting | No outcome recorded |
| Show all 134 trials opens the full record — a long page | ||||||
| Phase not applicable90 trials | ||||||
| — | NCT07568496 Comparator | May 2026 → Nov 2028 expected | migraine disorder | Mahidol University | Not yet recruiting | No outcome recorded |
| — | NCT07518277 Background | Apr 2026 → Apr 2028 expected | autoimmune hemolytic anemia, warm type | Chen Miao | Not yet recruiting | No outcome recorded |
| — | NCT07554885 Background | Apr 2026 → Dec 2028 expected | drug or radiation exposure-related interstitial lung disease, neoplasm | Guangzhou Institute of Respiratory Disease | Not yet recruiting | No outcome recorded |
| — | NCT07628166 Comparator | Mar → Apr 2026 | impacted teeth, multiple | Irfan Üstündağ | Completed | No outcome recorded |
| — | NCT07187037 Comparator | Oct 2025 → Apr 2026 overdue | curariform drugs toxicity | Konya City Hospital | Not yet recruiting | No outcome recorded |
| — | NCT04735185 Comparator | Sep → Nov 2025 | chronic pain syndrome, lumbar disk degenerative disorder | Johns Hopkins University | Withdrawn | No outcome recorded |
| — | NCT06916650 Comparator | Apr 2025 → May 2027 expected | frozen shoulder | Al Hayah University In Cairo | Recruiting | No outcome recorded |
| — | NCT06763848 Comparator | Apr 2025 → Dec 2026 expected | neuromyelitis optica | Third Affiliated Hospital, Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT07257588 Background | Sep 2024 → Dec 2025 overdue | ulcerative colitis | Xijing Hospital of Digestive Diseases | Enrolling by invitation | No outcome recorded |
| — | NCT06545812 Comparator | Sep 2024 → Mar 2026 | lumbar disk disease | Josip Juraj Strossmayer University of Osijek | Completed | No outcome recorded |
| — | NCT05927272 Background | Apr 2024 → Oct 2025 | vitiligo | University Hospital, Bordeaux | Unknown | No outcome recorded |
| — | NCT06710704 Comparator | Apr → Oct 2024 | epicondylitis | Tanta University | Completed | No outcome recorded |
| — | NCT05818150 Comparator | Jan 2024 → Apr 2026 overdue | osteoarthritis, knee | Merit Medical Systems, Inc. | Active not recruiting | No outcome recorded |
| — | NCT06198894 Comparator | Jan 2024 → Jan 2026 | chronic rhinosinusitis | Zheng Liu | Unknown | No outcome recorded |
| — | NCT06131593 Comparator | Dec 2023 → Apr 2024 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| — | NCT05925309 Background | Jul 2023 → Dec 2027 expected | biliary atresia, cholangitis | Children's Hospital of Fudan University | Recruiting | No outcome recorded |
| — | NCT05842681 Background | Jun 2023 → Jan 2027 expected | idiopathic pulmonary fibrosis | Assiut University | Recruiting | No outcome recorded |
| — | NCT05859412 Comparator | May 2023 → Aug 2025 | carpal tunnel syndrome | University of Oxford | Completed | No outcome recorded |
| — | NCT05930236 Background | Apr 2023 → Jun 2024 | chronic pain syndrome, vertebral column disorder | Erasme University Hospital | Unknown | No outcome recorded |
| — | NCT06236178 Comparator | Jan → Oct 2023 | epicondylitis | Istanbul Training and Research Hospital | Completed | No outcome recorded |
| — | NCT05782933 Comparator | Aug 2022 → Dec 2023 | idiopathic membranous glomerulonephritis | Beijing Friendship Hospital | Unknown | No outcome recorded |
| — | NCT05480566 Background | Jun 2022 → Dec 2023 | chronic obstructive pulmonary disease | Hasselt University | Terminated | No outcome recorded |
| — | NCT05971004 Comparator | Apr → Oct 2022 | enthesopathy | Tiss'You srl | Completed | No outcome recorded |
| — | NCT05563571 Comparator | Apr 2022 → Jan 2024 | arthropathy, stroke disorder | Satasairaala | Unknown | No outcome recorded |
| — | NCT05339542 Comparator | Mar → Jul 2022 | plantar fasciitis | Minia University | Completed | No outcome recorded |
| — | NCT05649878 Comparator | Nov 2021 | — | Edda Sciutto Conde | Completed | No outcome recorded |
| — | NCT05647291 Comparator | Oct 2021 → Apr 2022 | plantar fasciitis | Harran University | Completed | No outcome recorded |
| — | NCT06189586 Comparator | Oct 2021 → Dec 2024 | chronic obstructive pulmonary disease | Dong Yang | Unknown | No outcome recorded |
| — | NCT05137522 Background | Jul 2021 → Jul 2023 | hemophagocytic syndrome | Beijing Friendship Hospital | Unknown | No outcome recorded |
| — | NCT06082271 Comparator | May 2021 → Nov 2023 | osteoarthritis, hip | Rizzoli Orthopaedic Institute | Completed | No outcome recorded |
| — | NCT04808856 Comparator | Apr 2021 → Apr 2022 | gout | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
| — | NCT04709484 Background | Mar → Jun 2021 | plantar fasciitis | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | Completed | No outcome recorded |
| — | NCT04816253 Comparator | Feb → Jun 2021 | — | Al-Azhar University | Completed | No outcome recorded |
| — | NCT07049172 Background | Jan 2021 → Dec 2023 | nephrotic syndrome of childhood - steroid sensitive | Wuhan Children's Hospital | Completed | No outcome recorded |
| — | NCT04593706 Comparator | Nov 2020 → Oct 2021 | keloid, keloid formation | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT05925166 Comparator | Sep 2020 → Jul 2025 | gout | Lihua Duan | Completed | No outcome recorded |
| — | NCT04871633 Background | Aug → Nov 2020 | COVID-19 | King Edward Medical University | Completed | No outcome recorded |
| — | NCT04507165 Comparator | Aug 2020 → Jul 2021 | — | Peking University People's Hospital | Unknown | No outcome recorded |
| — | NCT04380818 Background | Jun 2020 → Sep 2021 | viral pneumonia | Grupo de Investigación Clínica en Oncología Radioterapia | Unknown | No outcome recorded |
| — | NCT05291793 Comparator | Apr 2020 → Jul 2021 | osteoarthritis, knee | Nevsehir Haci Bektas Veli University | Completed | No outcome recorded |
| — | NCT04129697 Comparator | Jan 2020 → Dec 2021 | sudden hearing loss disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT03724903 Comparator | Apr 2019 → Apr 2023 | granulomatous mastitis | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Completed | No outcome recorded |
| — | NCT03856229 Comparator | Mar 2019 → Aug 2026 overdue | HIV infectious disease, pneumocystosis | Center for Research in Infectious Diseases | Enrolling by invitation | No outcome recorded |
| — | NCT03742466 Comparator | Nov 2018 → Jul 2019 | carpal tunnel syndrome, chronic pain syndrome, scleroderma | Assiut University | Completed | No outcome recorded |
| — | NCT03586557 Comparator | Sep 2018 → Dec 2021 | optic neuritis | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT03412188 Comparator | Aug 2018 → Sep 2021 | autoimmune thrombocytopenic purpura | Nayera Hazaa Elsherif | Completed | No outcome recorded |
| — | NCT03466801 Comparator | Mar 2018 → Jan 2019 | idiopathic membranous glomerulonephritis | Wenhu Liu | Terminated | No outcome recorded |
| — | NCT03160651 Comparator | Feb 2018 → Jun 2022 | alcoholic hepatitis | Erasme University Hospital | Unknown | No outcome recorded |
| — | NCT03053401 Comparator | Feb 2017 → Oct 2019 | — | Akron Children's Hospital | Completed | No outcome recorded |
| — | NCT03058471 Comparator | Dec 2016 → Oct 2017 | chikungunya | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| — | NCT02936505 Background | Oct 2016 → Oct 2025 overdue | — | Vastra Gotaland Region | Active not recruiting | No outcome recorded |
| — | NCT02594241 Comparator | Mar 2016 → May 2018 | abdominal wall malformation | Kristian Kiim Jensen | Completed | No outcome recorded |
| — | NCT02591953 Background | Nov 2015 → May 2019 | tendinitis | Rush University Medical Center | Terminated | No outcome recorded |
| — | NCT02464696 Background | Oct 2015 → Oct 2026 expected | cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| — | NCT02304094 Comparator | Oct 2015 → Apr 2016 | Morton neuroma | Queen Margaret University | Unknown | No outcome recorded |
| — | NCT02669303 Comparator | Sep 2015 → Jan 2017 | shoulder impingement syndrome | American University of Beirut Medical Center | Terminated | No outcome recorded |
| — | NCT02367560 Comparator | Jul 2015 → Jun 2021 | calcific tendinitis | Lakehead University | Unknown | No outcome recorded |
| — | NCT02296346 Comparator | Oct 2014 → Jun 2017 | secondary progressive multiple sclerosis | University of Utah | Terminated | No outcome recorded |
| — | NCT05707572 Comparator | Sep 2014 → Sep 2018 | Morton neuroma | Dundee Podiatry Clinic | Completed | No outcome recorded |
| — | NCT02242630 Comparator | Sep 2014 → Mar 2016 | bursitis | Keesler Air Force Base Medical Center | Completed | No outcome recorded |
| — | NCT02219087 Comparator | Aug 2014 → Mar 2016 | osteoarthritis, knee | OhioHealth | Completed | No outcome recorded |
| — | NCT02197273 Background | Jul 2014 → Sep 2015 | osteoarthritis, hip, osteoarthritis, knee | OhioHealth | Completed | No outcome recorded |
| — | NCT02167698 Background | Feb 2014 → Jun 2016 | pediatric acute respiratory distress syndrome | Post Graduate Institute of Medical Education and Research, Chandigarh | Terminated | No outcome recorded |
| — | NCT02033408 Background | Jan 2014 → Dec 2018 | Crohn's colitis, ulcerative colitis | Shaare Zedek Medical Center | Completed | No outcome recorded |
| — | NCT02839577 Comparator | Dec 2013 → Jul 2014 | disease of the tendon | Bispebjerg Hospital | Completed | No outcome recorded |
| — | NCT02334475 Comparator | Jul 2013 → Dec 2014 | chronic pain syndrome | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| — | NCT07074951 Background | Mar 2013 → Mar 2026 overdue | IgA glomerulonephritis | St. Petersburg State Pavlov Medical University | Recruiting | No outcome recorded |
| — | NCT01755338 Comparator | Dec 2012 → Feb 2017 | aortic valve stenosis | Sahlgrenska University Hospital | Completed | No outcome recorded |
| — | NCT01579513 Comparator | Jun 2012 → May 2018 | congenital heart disease | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT01560052 Comparator | May 2012 → Jul 2021 | IgA glomerulonephritis | The George Institute | Completed | No outcome recorded |
| — | NCT03811366 Background | Jun 2011 → Jan 2017 | Vogt-Koyanagi-Harada disease, optic choroid disorder, vision disorder | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT01554930 Comparator | May → Nov 2010 | hand, foot and mouth disease | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| — | NCT01132677 Comparator | May 2010 → May 2011 | osteoarthritis, knee | LifeMark Health | Unknown | No outcome recorded |
| — | NCT02711982 Comparator | Jan 2010 → Dec 2020 | optic nerve disorder | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| — | NCT00989729 Comparator | Oct 2009 → Jan 2013 | abdominal aortic aneurysm | Louise de la Motte | Completed | No outcome recorded |
| — | NCT01397552 Comparator | Sep 2009 → Dec 2015 | lumbar disk disease, radiculitis | State University of New York - Upstate Medical University | Terminated | No outcome recorded |
| — | NCT00764413 Comparator | Apr 2009 → Jul 2012 | multiple sclerosis | Innlandet Hospital Trust | Terminated | No outcome recorded |
| — | NCT00805298 Comparator | Aug 2008 → Nov 2010 | — | University of Aarhus | Completed | No outcome recorded |
| — | NCT01420497 Comparator | Aug → Sep 2008 | diabetes mellitus | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| — | NCT01217099 Comparator | May 2007 → May 2010 | Mycoplasma pneumoniae pneumonia | Chongqing Medical University | Terminated | No outcome recorded |
| — | NCT00608517 Background | Sep 2005 → Mar 2008 | graft versus host disease, leukemia, myelodysplastic syndrome, plasma cell neoplasm | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| — | NCT00887003 Background | May 2005 → Aug 2011 | chronic pain syndrome | McMaster University | Completed | No outcome recorded |
| — | NCT01137084 Comparator | Jan 2005 → Jan 2008 | hepatocellular carcinoma, immunodeficiency disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| — | NCT00521430 Background | Apr 2004 → May 2008 | benign neoplasm, leukemia, myelodysplastic syndrome, plasma cell neoplasm | Asan Medical Center | Completed | No outcome recorded |
| — | NCT00068523 Background | Jun 2003 → Mar 2004 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloproliferative neoplasm +1 | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| — | NCT00348413 Background | Jun 2003 → Jul 2008 | disease of orbital part of eye adnexa | Singapore National Eye Centre | Completed | No outcome recorded |
| — | NCT00017654 Background | Apr 2001 → ? | aplastic anemia, graft versus host disease | Northwestern Memorial Hospital | Unknown | No outcome recorded |
| — | NCT00006055 Background | Mar 2000 → ? | Takayasu arteritis, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, eosinophilic granulomatosis with polyangiitis +8 | Fairview University Medical Center | Unknown | No outcome recorded |
| — | NCT00290628 Background | Oct 1999 → Apr 2007 | Diamond-Blackfan anemia, Fanconi anemia, graft versus host disease, leukemia +4 | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| — | NCT00798616 Comparator | — | bronchiolitis | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2005-02-24 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Methylprednisolone Acetate Injectable Suspension tevapharm.com ↗ |
Evidence & citations 49 cited values
Every value below carries the sentence it was read from. 1,042 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | methylprednisolone | “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗904“Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, which is administered concurrently with the...” NCT04078568 ↗ “Oral methylprednisolone tablets (brand name: Metrol®), 20 mg once daily for 14 consecutive days; following symptom relief, the dose should be gradually reduced every 1-2 weeks...” NCT07512648 ↗ “Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory...” NCT04233164 ↗ “Methylprednisolone sodium succinate 80 mg powder dissolved in 100 mL of sodium chloride solution (intravenous infusion, once daily) from the day of surgery to day 3, followed...” NCT07116811 ↗ “Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by...” NCT01621880 ↗ “Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally...” NCT03856229 ↗ “Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or...” NCT02169219 ↗ “high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1...” NCT04239196 ↗ “Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide,...” NCT03500133 ↗ “The following protocol describes a phase-3 multicentre, double-blinded, randomised, placebo-controlled trial to compare the effectiveness of methylprednisolone (62.5 mg/mL) to...” PMID 39209781 ↗ Aug 2024 “Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1 milliliter (mL) depo methylprednisolone (a steroid) and 2 mL 0.5% bupivacaine...” NCT04504812 ↗ “Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment...” NCT03721965 ↗ “Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of...” NCT03724903 ↗ “Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or...” NCT05921305 ↗ “Thus, the investigators suppose that pre-emptive scalp infiltration with steroid (methylprednisolone) plus local anesthetic (ropivacaine) could relieve postoperative pain after...” NCT04078139 ↗ “Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the...” NCT01994759 ↗ “Methylprednisolone was selected for its potent anti-inflammatory properties and lower mineralocorticoid activity, minimizing fluid retention while maximizing inflammatory suppression.” NCT07461961 ↗ “Patients with 10 or fewer days of fever were randomly assigned to receive intravenous methylprednisolone, 30 mg per kilogram of body weight (101 patients), or placebo (98 patients).” PMID 17301297 ↗ Feb 2007 “40mg sodium methylprednisolone succinate for injection(dissolved in 0.9% saline or5% glucose injection 50ml), intravenous infusion for 30 minutes, once a day for 5 consecutive days.” NCT06189586 ↗ “a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively.” NCT01680861 ↗ “This clinical trial employs a standard 3+3 design to establish the Recommended Phase 2 Dose (RP2D) of gecacitinib (also known as jaktinib) combined with methylprednisolone.” NCT07285889 ↗ “Transforaminal epidural steroid injection (ESI TF) with corticosteroids like Methylprednisolone, Levobupivacaine and Lidocaine according to the protocol of the institution.” NCT06545812 ↗ “The goal of this study is to examine the efficacy of 1gram/day intravenous pulses of methylprednisolone on 3 consecutive days in Behcet's patients with ocular involvement.” NCT01306955 ↗ “Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.” NCT02219087 ↗ “A single dose of 20 mg(1ml) of methyl-prednisolone (Depo-Medrol) (complemented to 1 ml by adding 0.5 ml of saline) was injected to the 1st CMC joint of the second group.” NCT06657300 ↗ “This is the first study to show that a single epidural steroid injection of 80 mg depot methylprednisolone had no effect on the glycemic control in diabetic patients.” PMID 22185681 ↗ Dec 2011 “Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.” NCT01576588 ↗ “Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml.” NCT02580630 ↗ “Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.” NCT02392286 ↗ “The intervention was weekly protocol or monthly protocol of IVGC; both received a cumulative dose of methylprednisolone 4.5 g and had a duration of 12 weeks.” PMID 37579198 ↗ Dec 2023 “Methylprednisolone 500 mg iv will be given for 3 consecutive days at the start of month 1,3,5 and followed by prednisone 0.5mg/kg/d (max 40mg/d) for 27 days.” NCT06781944 ↗ “Those patients assigned to the ESI group will receive epidural steroid injections with 80mg methylprednisolone and 10mg buvicaine to the interlaminar space.” NCT01934868 ↗ “Prednisone at a dose of 1-2 mg/kg/d (or an equivalent dose of methylprednisolone) is taken orally for 2-3 weeks, and then the dosage is reduced regularly.” NCT07518277 ↗ “Patients received corticosteroids at months 1, 3, and 5 (methylprednisolone 0.5 g at days 1, 2, and 3, then prednisone 0.5 mg/kg/d from day-4 to day-30).” NCT05782933 ↗ “will receive ultrasound-guided intra-articular SIJ injection with 40 mg of methylprednisolone with a uniform dose of 2 mL of 2% lidocaine hydrochloride.” NCT05134181 ↗ “Forty-two children (study group) received methylprednisolone (1 g/1.73 m2 per day for 3 days), ranitidine, ceftriaxone, and total parenteral nutrition.” PMID 24864182 ↗ Jun 2014 “standard of care combined with glucocorticoid(dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)” NCT05855395 ↗ “We randomly assigned 180 patients with ARDS of at least seven days' duration to receive either methylprednisolone or placebo in a double-blind fashion.” PMID 16625008 ↗ Apr 2006 “inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints” NCT03058471 ↗ “Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4);” NCT02084446 ↗ “Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.” NCT01244659 ↗ “Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion.” NCT03605238 ↗ “High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy” NCT01639339 ↗ “corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response” NCT04960644 ↗ “Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)” NCT06038422 ↗ “Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation.” NCT03644667 ↗ “1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.” NCT00279903 ↗ “active treatment with intravenous methylprednisolone pulses (control arm) administered every 4 Weeks (1 gram per infusion) for 52 weeks.” NCT02296346 ↗ “The AR episodes (subclinical, borderline, and Banff 1A)(26) were managed with IV methylprednisolone (MPD), 250 mg to 1 g for 3 to 5 days” NCT02328222 ↗ “One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent).” NCT01524068 ↗ “One gm of methylprednisolone I.V., on day 0, followed by 40 mg/day I.V. on days 1-4, and days 6-12 (or the P.O. prednisone equivalent).” NCT01266317 ↗ “Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II” NCT04958538 ↗ “The purpose of the study is to investigate whether the combination of rituximab and high dose methylprednisolone can be given together” NCT04981912 ↗ “Methylprednisolone (solumedrol) and prednisone are a group of medications called steroids that may be helpful for painful episodes.” NCT00263562 ↗ “1 gram/day of methylprednisolone IV for three days followed by 1mg/kg/day IV until inotropes weaning or 7 days whatever come first.” NCT06896253 ↗ “Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days” NCT04424862 ↗ “Prednisolone and methylprednisolone are also well known and used drugs, whose side effects are often dose and duration dependent.” NCT02571517 ↗ “combination of oral mini-pulse of methylprednisolone 16mg twice a week + phototherapy Ultraviolet B (UVB) TL01, 2 times a week.” NCT05927272 ↗ “Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days” NCT01614977 ↗ “Administration in association with Methylprednisolone IV (or Prednisolone PO) starting at 2 mg/kg/day in two administrations.” NCT05762640 ↗ “Participants were randomized 1:1 to the IV methylprednisolone sodium succinate (1000-mg) or oral prednisone (1250-mg) group.” PMID 29507942 ↗ Jun 2018 “Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days” NCT01205477 ↗ “Methylprednisolone (MP, "Solu-Medrol") is one such glucocorticoid, which has been shown to be safe for usage in surgery.” NCT02594241 ↗ “Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.” NCT05177237 ↗ “Patients with acute grade II GVHD are treated with a combination of methylprednisolone (0.5 mg/kg/day) and ruxolitinib.” NCT07576010 ↗ “Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)” NCT03317197 ↗ “A pulse regimen of IV methylprednisolone at 250 mg daily (days 1 to 3), with no additional corticosteroids thereafter.” NCT07299695 ↗ “High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.” NCT01191190 ↗ “Other forms of corticosteroids are also acceptable e.g. hydrocortisone, methylprednisolone at the equivalent dosage.” NCT06446245 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT04843761 ↗ “In the first case, methylprednisolone will be administered intravenously for 1-3 days at the dosage of 500-1000 mg.” NCT07074951 ↗ “Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)” NCT02319343 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT06729593 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT06729606 ↗ “Methylprednisolone 100 mg i.v. will be administered on days 6 and 15, as a premedication prior to the rituximab.” NCT03286556 ↗ “a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered” NCT00687011 ↗ “Groups were given oral methylprednisolone (32 mg/d on days 1-5; 16 mg/d on days 6-10; and 8 mg/d on days 11-20),” NCT06198894 ↗ “Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 3 days, then taper according to the clinical response.” NCT04061876 ↗ “3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.” NCT02340936 ↗ “Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.” NCT07340723 ↗ “125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone” NCT03292861 ↗ “Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)” NCT02936596 ↗ “The first group received an intramuscular injection of Methylprednisolone 40 mg/ml 2ml x 1 as a single dose.” NCT04622917 ↗ “IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months” NCT01154387 ↗ “Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS” NCT05789589 ↗ “Doses of iv rituximab (1 g) were given on d 1 and 15, after pretreatment with 125 mg iv methylprednisolone.” PMID 22767640 ↗ Jul 2012 “Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis.” NCT04397367 ↗ “early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers” NCT04530409 ↗ “Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month.” NCT01998633 ↗ “Intraperitoneal methylprednisolone (1mg/kg/day) will be administered every day for 1 week postoperatively.” NCT06185426 ↗ “ESHAP (etoposide, methylprednisolone, cisplatin, cytosine arabinoside) chemotherapy was invented in 1994.” NCT00930605 ↗ “Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride” NCT02332629 ↗ “Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant.” NCT01015742 ↗ “Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.” NCT02922374 ↗ “systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV” NCT02872597 ↗ “Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.” NCT04738318 ↗ “Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg” NCT02351427 ↗ “The control group received a median nerve perineural injection of bupivacaine with methylprednisolone.” PMID 40804365 ↗ Aug 2025 “Permitted at investigator's discretion: intravenous methylprednisolone pulse therapy (dose 0.25-3.0g).” NCT07340463 ↗ “The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.” NCT04709484 ↗ “Methylprednisolone is a corticosteroid with anti-inflammatory properties and immune suppression.” NCT06780202 ↗ “dexamethasone 8mg, methylprednisolone 80mg and bupivacaine 5ml 0.25%, intra articular injection” NCT07489521 ↗ “IVMP arm: 1000mg methylprednisolone x5d, oral prednisone 60mg, 5mg weekly decline + antibiotics” NCT06673394 ↗ “Methylprednisolone (0.5 mg/kg/day, oral, tapered over 12 weeks according to protocol) + Placebo” NCT06925698 ↗ “Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.” NCT00582816 ↗ “Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room” NCT00035555 ↗ “methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5” NCT00755859 ↗ “oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable” NCT02442180 ↗ “Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.” NCT03497273 ↗ “methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended)” NCT03635957 ↗ “40 mg of local methylprednisolone (depomedrol) injection will be applied to Group 1 once.” NCT03792945 ↗ “The participants received 500 mg methylprednisolone intravenously for 3 consecutive days.” PMID 38287611 ↗ Jul 2021 “Control group receives 80 mg Methylprednisolone while the test group receives phenol 8%.” NCT01468415 ↗ “Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d).” NCT05674994 ↗ “The active group will be administered 2 mls of 2% lidocaine and 80mg methylprednisolone.” NCT04017741 ↗ “Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc.” NCT01285674 ↗ “Solu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration” NCT02798068 ↗ “Combined Vasopressin, Methylprednisolone, and Epinephrine for Inhospital Cardiac Arrest” NCT00411879 ↗ “either brand name or non-particulate betamethasone [6 mg] or methylprednisolone [40 mg]” PMID 21267039 ↗ Jan 2011 “Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.” NCT00849355 ↗ “500mg methylprednisolone was intravenously injected once a day for 3 consecutive days.” NCT07152366 ↗ “500mg methylprednisolone was intravenously injected once a day for 3 consecutive days.” NCT07152340 ↗ “methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD” NCT00745420 ↗ “Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.” NCT04692376 ↗ “treatment in the PS group consisted of methylprednisolone 40 mg (intravenous ampoule)” NCT01865500 ↗ “0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day” NCT01002339 ↗ “steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase” NCT00296244 ↗ “Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated” NCT02936375 ↗ “MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A” NCT00323960 ↗ “methylprednisolone 0.8mg/kg/day (or equivalent corticosteroid doses) for 3 weeks” NCT03384277 ↗ “methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours” NCT05187793 ↗ “High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper” NCT03586557 ↗ “intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days” NCT00354198 ↗ “Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days” NCT04996303 ↗ “ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic.” NCT03456817 ↗ “in the form of methylprednisolone (1,000mg daily) administered intravenously” NCT07100990 ↗ “Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)” NCT05819541 ↗ “500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.” NCT01296074 ↗ “12 pulses of intravenous methylprednisolone (IVMP) in every week schedule” NCT03667157 ↗ “Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent” NCT01435291 ↗ “2 doses of Rituximab 1 g and Methylprednisolone 500 mg on days 1 and 15.” NCT05207358 ↗ “a single IV infusion of methylprednisolone 500 mg will be administrated” NCT05679336 ↗ “* i.v. methylprednisolone 1000 mg on days 1,2,3, 60,61,62, 120,121,122” NCT00135954 ↗ “glucocorticosteroid (prednisone, dexamethasone or methylprednisolone)” NCT02188368 ↗ “Each rituximab infusion was preceded by methylprednisolone 100 mg IV.” NCT00443651 ↗ “Methylprednisolone 1.5 mg/kg days 1 to day 3, 0.25mg/kg days 4 to 14” NCT05164978 ↗ “three-day course of intravenous methylprednisolone (1000 mg per day)” NCT03811366 ↗ “substitute IV methylprednisolone at 80% of the oral prednisone dose” NCT01186328 ↗ “standard a standard combination of methylprednisolone and lidocaine” NCT07217405 ↗ “methylprednisolone (infusion) prior to each Thymoglobulin infusion” NCT02137239 ↗ “Methylprednisolone at a dose of 2 mg/kg/day for 3 consecutive days” NCT06870448 ↗ “IM GC arm: Single dose 120 mg IM methylprednisolone to the deltoid” NCT07245732 ↗ “Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days” NCT04374539 ↗ “methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses” NCT02033408 ↗ “Methylprednisolone 100 mg (or equivalent) orally or intravenously” NCT05807048 ↗ “the steroid methylprednisolone (40 mg/mL) into each affected disc” NCT04735185 ↗ “Oral Glucocorticoids（methylprednisolone） 24mg qd, 2-week duration” NCT05598424 ↗ “Corticosteroids (Prednisone, or IV methylprednisolone equivalent)” NCT05123040 ↗ “methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4” NCT03113695 ↗ “methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14” NCT05315336 ↗ “ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin)” NCT00568815 ↗ “Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate” NCT03917797 ↗ “500-mg pulse of methylprednisolone given on days 10, 11, and 12” NCT00801632 ↗ “oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months” NCT02173106 ↗ “pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day.” NCT00849888 ↗ “Intravenous injection of methylprednisolone (IVMP) for 14 days” NCT07410039 ↗ “Intravenous methylprednisolone (IVMP) 1000 mg daily for 3 days” NCT07420296 ↗ “methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14” NCT05775705 ↗ “Corticosteroids (methylprednisolone/dexamethasone/prednisone)” NCT04380818 ↗ “Methylprednisolone will be administered on Days 1 through 3.” NCT01729494 ↗ “prednisone,methylprednisolone,corticosteroid,hydrocortisone” NCT00842933 ↗ “Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)” NCT02133924 ↗ “methylprednisolone intravenous 15-30mg/kg/d (Max.500mg/d)” NCT05969522 ↗ “pulse steroid (250 mg/day methylprednisolone for 5 days)” NCT06223984 ↗ “Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID” NCT00294684 ↗ “topical Methylprednisolone 0.1% over affected skin area” NCT01902836 ↗ “induction : pulse methyl prednisolone (7 mg/kg/day x3)” NCT01275287 ↗ “prednisone, methylprednisone, methylprednisolone, etc.” NCT01950819 ↗ “40mg/1ml methylprednisolone, two sessions once a week” NCT05647291 ↗ “2 mg/kg/day of IV methylprednisolone for three days.” NCT04680884 ↗ “a steroid bolus (methyl-prednisolone 500 mg, day -1)” NCT01346085 ↗ “1,000 mg/m2 Methylprednisolone will be administered.” NCT02229422 ↗ “500+500mg methylprednisolone iv. before reperfusion” NCT02936505 ↗ “Betamethasone, dexamethasone, or methylprednisolone” NCT05401812 ↗ “methylprednisolone (three bolus doses of 15 mg/kg)” NCT06680349 ↗ “Methylprednisolone 1000 mg intravenous for 3 days” NCT01870128 ↗ “methylprednisolone 1g/m2(up to 1.5g) IV day1-day5” NCT01670812 ↗ “1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses” NCT00707759 ↗ “methylprednisolone 500mg/day IV on Days 1-4 or 5” NCT03391466 ↗ “Standard PAI + 40mg methylprednisolone (n = 40)” NCT07151417 ↗ “2. Methylprednisolone (for severe/acute cases):” NCT03692416 ↗ “Methylprednisolone (high-dose tapering regimen)” NCT07519005 ↗ “multiple sclerosis (ACTH, methylprednisolone)” NCT02670161 ↗ “Methylprednisolone(MP) was injected for 3 day” NCT03466801 ↗ “Other Name: Prednisolone / Methylprednisolone” NCT07098897 ↗ “Low dose oral methyl prednisolone was added.” NCT04935515 ↗ “prednisone, methylprednisolone, prednisolone” NCT06585774 ↗ “prednisone, prednisolone, methylprednisolone” NCT06388564 ↗ “methylprednisolone (Depo-Medrol) 4 mg per cc” NCT03009500 ↗ “Methylprednisolone for injection 60 mg/day.” NCT07546097 ↗ “methylprednisolone 40mg (intravenous bolus)” NCT04507165 ↗ “methylprednisolone (Solu-Medrol® 40mg/vial)” NCT06203847 ↗ “methylprednisolone 24mg qd, 2-week duration” NCT05598411 ↗ “Methylprednisolone 40 mg IV q8hrs x 3 days” NCT01742338 ↗ “Methylprednisolone 1-2mg/kg for 5-7 days” NCT04853901 ↗ “Methylprednisolone 100 mg TD IV day -8” NCT01612988 ↗ “intravenous methylprednisolone (IVMP)” NCT07410039 ↗ “Methylprednisolone 0.5mg/kg ivgtt qd” NCT07152613 ↗ “methylprednisolone 1.6 mg/kg/day IV” NCT05643638 ↗ “Receive 0.5mg/kg Methylprednisolone” NCT07152587 ↗ “IV methylprednisolone (2 mg/kg/day)” NCT07049172 ↗ “methylprednisolone and prednisolone” NCT00554502 ↗ “Triamcinolone or methylprednisolone” NCT05818150 ↗ “Methylprednisolone or equivalent:” NCT00617604 ↗ “Methylprednisolone, Depo-medrol” NCT03232749 ↗ “methylprednisolone 1 mg/kg d1-3” NCT06504030 ↗ “dd -2 to 1: Methylprednisolone” NCT01516593 ↗ “Methylprednisolone 500mg, D1-5” NCT01300156 ↗ “Methylprednisolone 250mg/m2 D6” NCT02431403 ↗ “methylprednisolone 500mg D1-4” NCT05244642 ↗ “IV Methylprednisolone: 40 mg” NCT05136976 ↗ “Drug: methylprednisolone” NCT03533790 ↗ “methylprednisolone taper” NCT07158476 ↗ “Methyl-prednisolone” NCT00284947 ↗ “Methylprednisolone” NCT03752307 ↗ “Methylprednisolone” NCT06697535 ↗ “methylprednisolone” NCT02147015 ↗ “methylprednisolone” NCT04553003 ↗ “Methylprednisolone” NCT03818737 ↗ “Methylprednisolone” NCT00933231 ↗ |
| Known as | 6-methyl-prednisolone | “0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1” NCT02540395 ↗ |
| Known as | acetate methylprednisolone | “The goal of this study was double, at first comparing the glycaemic profile in diabetic patients after a unique injection of 80 mg of acetate methylprednisolone either...” PMID 22185681 ↗ Dec 2011 |
| Known as | BMMSCs= Bone Marrow Mesenchymal Stem Cells | “BMMSCs= Bone Marrow Mesenchymal Stem Cells” NCT01909154 ↗ |
| Known as | Danalone | “Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days” NCT01614977 ↗ |
| Known as | DEPO-MEDROL | “Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120...” NCT01238536 ↗40“one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar...” NCT05971004 ↗ “Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the suprapatellar pouch.” NCT01923909 ↗ “Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline” NCT03543033 ↗ “Prior to surgical closure, patients received 1 ml of either Depo-Medrol (DEPO) or saline (NODEPO) applied to a Gelfoam carrier at the surgical site.” PMID 29676673 ↗ Apr 2018 “Participants receive 1-3 ultrasound-guided peritendinous injections of Depo-Medrol (methylprednisolone acetate 40 mg) combined with lidocaine.” NCT07650396 ↗ “Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)” NCT04980105 ↗ “Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure” NCT03311425 ↗ “Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure” NCT03308084 ↗ “1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin.” NCT01945749 ↗ “Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)” NCT02103543 ↗ “Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)” NCT01983527 ↗ “40 mg of local methylprednisolone (depomedrol) injection will be applied to Group 1 once.” NCT03792945 ↗ “0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml)” NCT04515966 ↗ “DEPO-MEDROL 40 mg/ml + 1 cc di NAROPINA 0,75% 7,5 mg/ml” NCT06082271 ↗ “Methylprednisolone (40 mg depomedrol, 1ml, injection)” NCT02867904 ↗ “Methylprednisolone Acetate 40 MG/ML [Depo-Medrol]” NCT04942002 ↗ “methylprednisolone (Depo-Medrol) 4 mg per cc” NCT03009500 ↗ “1mL of Depomedrol (Methylprednisolone) 40mg” NCT05930236 ↗ “Pfizer Depo-medrol” NCT06532318 ↗ “Depo-Medrol 40mg” NCT02039804 ↗ “Depo-Medrol” NCT05440240 ↗ |
| Known as | DepoMedrone | “The steroid is a drug called "DepoMedrone."” NCT02038452 ↗ |
| Known as | Depot Methylprednisolone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02283996 ↗ |
| Known as | Group A SLE prospective study | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00987831 ↗ |
| Known as | HDMP | “All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:
•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered.” NCT02229422 ↗2“High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.” NCT01191190 ↗ “methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4” NCT03113695 ↗ |
| Known as | High Volume injection with corticosteroid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02839577 ↗ |
| Known as | High-dose methylprednisolone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04862221 ↗ |
| Known as | IVMP | “OBJECTIVE: To compare intravenous methylprednisolone (IVMP) with oral prednisolone (OP) for the treatment of West syndrome.” PMID 33575989 ↗ Feb 20218“Participants randomised to the control arm will receive standard therapy of intravenous methylprednisolone (IVMP).” PMID 26009577 ↗ May 2015 “intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)” NCT03542279 ↗ “12 pulses of intravenous methylprednisolone (IVMP) in every week schedule” NCT03667157 ↗ “Intravenous injection of methylprednisolone (IVMP) for 14 days” NCT07410039 ↗ “Intravenous methylprednisolone (IVMP) 1000 mg daily for 3 days” NCT07420296 ↗ “Intravenous Methylprednisolone (IVMP)” NCT07184840 ↗ “methylprednisolone (IVMP)” NCT00934843 ↗ |
| Known as | Medrol | “Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of...” NCT03724903 ↗11“Methylprednisolone will be administered once a day either in tablets; Medrol 1g per day or iv; Solumedrol 1000 mg per day, both for three consecutive days.” NCT03674099 ↗ “Patients will receive 3 mg of methylprednisolone once daily. The dose is administered in the morning (1 ½ tablets of 2 mg Medrol after breakfast).” NCT07703098 ↗ “Therapeutic Interventions. Methylprednisolone (Medrol®) dose pack.” NCT03529929 ↗ “methylprednisolone - Medrol, 16mg Pfizer Laboratories” NCT05941130 ↗ “Medrol 4 MG Oral Tablet Includes Medrol Dosepak” NCT07158476 ↗ |
| Known as | Medrol Dose Pack | “Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.” NCT01874860 ↗1“Therapeutic Interventions. Methylprednisolone (Medrol®) dose pack.” NCT03529929 ↗ |
| Known as | Medrol Dosepak | “1. Medrol Dosepak, take per package instructions from postoperative day 1 to postoperative day 6.” NCT06561035 ↗1“Medrol 4 MG Oral Tablet Includes Medrol Dosepak” NCT07158476 ↗ |
| Known as | MEP | “Single dose of MEP sodium succinate intravenously administered. MEP (equivalent to 62.5 mg of Methylprednisolone).” NCT05649878 ↗ |
| Known as | MEP sodium succinate | “Single dose of MEP sodium succinate intravenously administered. MEP (equivalent to 62.5 mg of Methylprednisolone).” NCT05649878 ↗ |
| Known as | MePRDL | “then intravenous methylprednisolone (MePRDL) tapered over the next 34 days” NCT00004785 ↗4“One group receives a 24-hour methylprednisolone (MePRDL) infusion:” NCT00004759 ↗ “Methylprednisolone, MePRDL, NSC-19987” NCT00002471 ↗ “MePRDL Methylprednisolone, NSC-19987” NCT00002599 ↗ “MePRDL Methylprednisolone succinate” NCT00002565 ↗ |
| Known as | Mesenchymal stromal cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01909154 ↗ |
| Known as | Methylprednisolon | “1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin.” NCT01945749 ↗ |
| Known as | Methylprednisolone (Medrol) | “Methylprednisolone (Medrol)” NCT04438382 ↗1“Methylprednisolone (Medrol)” NCT01332617 ↗ |
| Known as | Methylprednisolone (Solumedrol) | “Methylprednisolone (Solumedrol)” NCT00296244 ↗1“Methylprednisolone, Solu-medrol” NCT01647685 ↗ |
| Known as | Methylprednisolone acetate | “Single injection into the glenohumeral joint under ultrasound guidance. Consists of 40 mg methylprednisolone acetate combined with 4 ml of 1% lidocaine hydrochloride. Delivered...” NCT06916650 ↗43“Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle...” NCT00947765 ↗ “Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .” NCT03704584 ↗ “Group l include 50 patients who will be injected with one intra\_articular injection of 2 ml of methylprednisolone acetate 40 mg/ml mixed with 2ml of lidocaine” NCT05742061 ↗ “Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).” NCT03053401 ↗ “Intra-articular injection consisting of 80 mg of methylprednisolone acetate, 2 mL of lidocaine (1%), and 4 mL of ropivacaine (0.5%)” NCT07497737 ↗ “Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure” NCT03311425 ↗ “This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine” NCT02044991 ↗ “Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure” NCT03308084 ↗ “Participants in the CS category were given 1 ml of 40 mg methylprednisolone acetate mixed with 2 ml of 2% prilocaine HCl.” PMID 38963583 ↗ Jul 2024 “Methylprednisolone acetate (MPA)(Depomedrol) is a lipophilic glucocorticoid commonly used in chronic pain procedures.” NCT05893771 ↗ “Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)” NCT01983527 ↗ “Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.” NCT03728478 ↗ “1ml of methylprednisolone acetate (40mg/ml) injection into subacromial bursa.” NCT06631976 ↗ “dexamethasone sodium phosphate (DEX) and methylprednisolone acetate (MPA)” NCT03977454 ↗ “epidural administration of methylprednisolone acetate (40 mg)” NCT07411950 ↗ “0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml)” NCT04515966 ↗ “Methylprednisolone acetate 20mg/ml injection” NCT06532318 ↗ |
| Known as | methylprednisolone acetate (Depo-Medrol) | “methylprednisolone acetate (Depo-Medrol)” NCT04438382 ↗ |
| Known as | Methylprednisolone Sodium Succinate | “Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory...” NCT04233164 ↗26“Methylprednisolone sodium succinate is a synthetic glucocorticoid (corticosteroid) administered intravenously at a single dose of 125 mg one hour prior to the surgical...” NCT07317596 ↗ “The study determined if the administration of the corticosteroid, methylprednisolone sodium succinate, in severe ARDS that was either stable or worsening after 7 days, would...” NCT00000579 ↗ “Methylprednisolone Sodium Succinate can reduce the disruption of the blood-brain barrier and inflammatory response in animal models of intracerebral hemorrhage, and alleviate...” NCT06921616 ↗ “Methylprednisolone sodium succinate can reduce the disruption of the blood-brain barrier and inflammatory response in animal models of intracerebral hemorrhage, and alleviate...” NCT06924983 ↗ “Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)” NCT00186628 ↗ “This clinical study involves a perioperative pharmacological intervention using Methylprednisolone (Methylprednisolone Sodium Succinate for injection).” NCT07353749 ↗ “Participants were randomized 1:1 to the IV methylprednisolone sodium succinate (1000-mg) or oral prednisone (1250-mg) group.” PMID 29507942 ↗ Jun 2018 “Patients will be treated with injectable methylprednisolone sodium succinate as described in Arm A.” NCT06497374 ↗ “Solu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration” NCT02798068 ↗ “methylprednisolone sodium succinate equivalent to 62.5 mg of methylprednisolone” NCT05649878 ↗ “Hydrocortisone or Methylprednisolone sodium succinate” NCT04381936 ↗ “Drug: Methylprednisolone Sodium Succinate” NCT03082092 ↗ “Drug: Methylprednisolone sodium succinate” NCT06462781 ↗ “Drug: Methylprednisolone sodium succinate” NCT07054801 ↗ “methylprednisolone sodium succinate” NCT01726465 ↗ |
| Known as | Methylprednisolone sodium succinate (Solu-Medrol) | “Methylprednisolone sodium succinate (Solu-Medrol)” NCT04438382 ↗ |
| Known as | Methylprednisolone Succinate | “Patients assigned to the corticosteroid group will receive (pulse) methylprednisolone succinate 500-1000 mg/day for 3 consecutive days followed by oral prednisolone (0.5...” NCT04662723 ↗4“Evaluation of the Bioavailability of Methylprednisolone Succinate Administered Intranasally” NCT05649878 ↗ “Drug: Methylprednisolone succinate 500 mg” NCT05748561 ↗ “MePRDL Methylprednisolone succinate” NCT00002565 ↗ |
| Known as | Methylprednisolone, generic | “Methylprednisolone, generic” NCT01809132 ↗ |
| Known as | Methylprednisolone, MP | “Methylprednisolone, MP” NCT04192656 ↗ |
| Known as | Metil prednisolone | “Drug: Metil prednisolone” NCT01865500 ↗ |
| Known as | Metrol | “Oral methylprednisolone tablets (brand name: Metrol®), 20 mg once daily for 14 consecutive days; following symptom relief, the dose should be gradually reduced every 1-2 weeks...” NCT07512648 ↗ |
| Known as | metylprednisolone | “Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a...” NCT01205984 ↗ |
| Known as | MPA | “Methylprednisolone acetate (MPA)(Depomedrol) is a lipophilic glucocorticoid commonly used in chronic pain procedures.” NCT05893771 ↗2“Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate (B-DEX-MPA)” NCT05279092 ↗ “dexamethasone sodium phosphate (DEX) and methylprednisolone acetate (MPA)” NCT03977454 ↗ |
| Known as | MPD | “The AR episodes (subclinical, borderline, and Banff 1A)(26) were managed with IV methylprednisolone (MPD), 250 mg to 1 g for 3 to 5 days” NCT02328222 ↗ |
| Known as | MPDN | “MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A” NCT00323960 ↗ |
| Known as | mPSL | “methylprednisolone sodium succinate (mPSL)” NCT00627731 ↗ |
| Known as | NPB-01-ME | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05177939 ↗ |
| Known as | NSC-19987 | “Methylprednisolone, MePRDL, NSC-19987” NCT00002471 ↗1“MePRDL Methylprednisolone, NSC-19987” NCT00002599 ↗ |
| Known as | Prednol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04532736 ↗ |
| Known as | Prednol-L 40mg | “Corticosteroid Injection category were given 1ml of 40 mg methylprednisolone acetate(Prednol-L 40mg,Mustafa Nevzat,Turkey) mixed with 2ml of 2% prilocaine HCl(Priloc...” NCT06236178 ↗ |
| Known as | Solu-Medrol | “Control Group : A 22-gauge needle of venous cannula will be gently advanced in transverse direction under ultrasound guidance using the in-plane technique via ulnar side of...” NCT05053477 ↗34“Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory...” NCT04233164 ↗ “Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day...” NCT02439866 ↗ “Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)” NCT00186628 ↗ “The active study medicine is 2 x 125 mg/2 mL Solu-Medrol, a total of 250 mg/4 mL, which comes as a sterile powder with preservative free isotonic NaCl as diluent.” NCT07478003 ↗ “Methylprednisolone will be administered once a day either in tablets; Medrol 1g per day or iv; Solumedrol 1000 mg per day, both for three consecutive days.” NCT03674099 ↗ “Injection into capsular tissue after placement of the acetabular component: 0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline” NCT02197273 ↗ “prepared by dilution of methyleprednisolone 500mg in 10 ml distilled water (Solu-Medrol, Pfizer company)” NCT04318652 ↗ “Solumedrol, dexamethasone,prednisolone, azithromycin” NCT04871633 ↗ “Methylprednisolone sodium succinate(Solu-Medrol)” NCT02798523 ↗ “40 mg methylprednisolone (Solu-medrol®, Pfizer)” NCT03640949 ↗ “methylprednisolone (Solu-Medrol® 40mg/vial)” NCT06203847 ↗ “Solumedrol \[250 mg/day IV, D1-4\]” NCT04378647 ↗ “methylprednisolone (Solumedrol)” NCT03456817 ↗ “Solu-Medrol” NCT05462730 ↗ “Solu-medrol” NCT03583151 ↗ “Solu-Medrol” NCT00545402 ↗ “solumedrol” NCT03412188 ↗ |
| Known as | Solu-Medrolw | “The MP group received a single-dose of MP, 1 mg/Kg i.v. (Solu-Medrolw; Pfizer, Ballerup, Denmark)” NCT03393949 ↗ |
| Known as | Soludomerin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02243436 ↗ |
| Known as | Step-up | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01752790 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as etoposide, methylprednisolone, cytarabine, and cisplatin, work in different ways to stop the growth of cancer cells, either by killing the...” NCT00310128 ↗ |
| Modality | Other / unclassified | “corticosteroid treatment” NCT00000146 ↗ |
| Route | Intravenous | “Intravenous methylprednisolone” NCT00000146 ↗ |
| Target | AQP2 | “methylprednisolone up regulates u-AQP-2” NCT00281710 ↗ |